Compare

Enclomiphene vs Melanotan II

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Enclomiphene

2235 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 69% · Mixed 20% · Unfavorable overall 11%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
54
Digestive comfort
62
Skin appearance
63
Appetite control
153
Energy
164

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
150
Flushing
141
Headache
28
GI discomfort
149
Dizziness
164

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05–5 mg

0.05–0.1 mg
4
0.1–0.2 mg
7
0.2–0.4 mg
16
0.4–0.6 mg
20
0.6–1 mg
25
1–2 mg
22
2–3 mg
17
3–5 mg
11

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing39stacking42side effects35enclomiphene18

How repeat users are trending

Among repeat reporters, 64% said they felt similar to their last entry, 43% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 32 days · Based on 492 repeat reporters

Melanotan II

1450 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-167
Focus
12
Sleep quality
-101
Lean mass
-48
Joint comfort
-18

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-71
Nausea
-89
Water retention
-136
Appetite loss
-52
Injection site reaction
-19

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–3 mg

0.05–0.1 mg
2
0.1–0.2 mg
5
0.2–0.4 mg
14
0.4–0.6 mg
22
0.6–1 mg
11
1–2 mg
2
2–3 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing14stacking42side effects30melanotan ii8

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 18 days · Based on 319 repeat reporters

Sources (6)

Published sources linked on the Enclomiphene and Melanotan II wiki pages.

  1. PubMed

    Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement

    Kim ED, McCullough A, Kaminetsky J, et al. BJU Int. 2016

    Source
    Wiki study page →
  2. PubMed

    Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics

    Wiehle R, Cunningham GR, Pitteloud N, et al. BJU international. 2013

    Source
    Wiki study page →
  3. PubMed

    Enclomiphene citrate for the treatment of secondary male hypogonadism

    Rodriguez KM, Pastuszak AW, Lipshultz LI. Expert opinion on pharmacotherapy. 2016

    Source
    Wiki study page →
  4. PubMed

    LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs

    Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021

    Source
    Wiki study page →
  5. PubMed

    Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

    Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012

    Source
    Wiki study page →